Pharmacoeconomic review report: Sucroferric oxyhydroxide (Velphoro) (Vifor Fresenius Medical Care Renal Pharma Ltd.) indication : for the control of serum phosphorus levels in adult patients with end-stage renal disease on dialysis

Sucroferric oxyhydroxide (500 mg; Velphoro) is a non-calcium, iron-based, chewable phosphate binder indicated for the control of serum phosphorus levels in patients with end-stage renal disease (ESRD) receiving dialysis. The starting dosage is three tablets per day (1,500 mg iron) administered as on...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH February 2019, 2019
Edition:	Final
Series:	CADTH common drug review
Subjects:	Ferric Oxide, Saccharated / Economics Comparative Effectiveness Research Hyperphosphatemia / Drug Therapy Canada Renal Insufficiency, Chronic / Drug Therapy Quality-adjusted Life Years Cost-benefit Analysis Ferric Oxide, Saccharated / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK542813
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa